Traders love the health promotion for the lottery ticket - as the gate they have every chance to offer, in case the firm hits the medical gold. Sample: promotions OncoCyte (OCX) very quickly grow by almost 220% (Yes, you read right!) on Tuesday at a trading session, subsequently such as the diagnostic firm announced positive data from a validation study demonstrating the accuracy of its own watery biopsy test, Determinavu, for non-severe cancer.

DetermaVu developed in order to eliminate patients in whom there are suspicious nodule mild, but not urge an immediate biopsy. Fortunately for the firm and traders, the validation study demonstrated that Determinavu is able to generate 90% affect, 75% specificity and area under the curve (AUC).89. Focusing on the results, the firm does not stand on the commercialization of efforts, with the launch scheduled for 2X19.

In response, the analyst at Lake Street Thomas Flaten repeated the rating of purchase promotions OCX, increasing their price goal to $7,00 ($4,00), in fact that involves the upgrade of approximately 19% from current values.

Flaten commented: "we believe that the current results are considered to be a convincing confirmation of the firm's ability to move forward with a commercially viable product, offering a reliable diagnostic conclusion for a critical need in the market and applying gigantic market capabilities. We approve our acquisition rating and raise our motivated value score to $7 to reflect the risk reduction that has happened to the positive results of the study on the R&d audit.”

"The completion of validation studies and paid availability in 2H19 clarifies OCX on a fairly long road to getting a refund, a dangerous step in seeing paid triumph with Determinavu. We expect actually that to obtain compensation for a wide base of support Medicare and fee-payers have an opportunity to take up to 3 years. OPAS steps on this path include the publication of the results of the study validation of R & d (6-18 months), the introduction of this publication in the research centres for the study of medical usefulness and execution of a clinical study utility, the main variable in the aid of reimbursable status. In the crotch stage are we waiting for, exactly what firm will give the earnings, however the real pay-the triumph comes with wide refund", - said the analyst.